Lyophilized Injectable Drugs Market Size - By Drug type (Anti-infectives, Anticoagulants, Hormones), Indication (Autoimmune, Respiratory, Gastrointestinal, Oncology), Packaging Type (Vial), Distribution Channel, Delivery Type, Global Forecast, 2023-2032

Lyophilized Injectable Drugs Industry Analysis

Lyophilized Injectable Drugs Market size reached over USD 280 billion in 2022 and is poised to record 13.5% CAGR by 2032 attributed to the increasing research, development, as well as commercialization of novel drugs to cater to varied disease treatment.
 

To get more details on this report: Request Free Sample PDF
 

Numerous companies are collaborating with several other players for fastening their discovery process and boosting the product development capabilities of the organization. Several pharmaceutical firms are also harnessing external sources of technologies and R&D activities to bring innovations.  For instance, Pfizer, in May 2022, established its drug R&D center in India for developing active pharmaceutical ingredients as well as finished dosage forms, such as lyophilized injectables. The increasing collaboration of contract research manufacturing services (CRAMS) with major pharmaceutical companies for scaling up their operational capabilities for injectable drugs.

The rising costs associated with the manufacturing process, particularly the integration of innovative technologies into lyophilized injectables drug delivery systems will act as a restraint for the business gains. The escalating prices related to the development of novel technologies, including dual chamber syringes, cartridges, and others.
 

COVID-19 Impact

The COVID-19 pandemic positively influenced the adoption of lyophilized injectable drugs due to the surging demand for therapeutics and diagnostic tests. The rapidly increasing intervention of pharmaceutical and biotechnology companies led to the rising preference for diagnosis, treatment, and prevention of COVID-19. Therefore, the increased instances of COVID-19 vaccine development and supply along with the influx of new lyophilized injectable drugs to offer high performance and optimization.
 

Lyophilized Injectable Drugs Market Trends

The surging count of product approvals for lyophilized injectable drugs will complement the industry expansion. The robust presence of major market players has led to the increase in product availability and accessibility. The rising number of several clinical studies undertaken by various organizations for securing product approvals to cater to the extended applications of lyophilized injectables drugs for treating cancer and other diseased patients.
 

Lyophilized Injectable Drugs Segmentation by Drug Type

To get more details on this report: Request Free Sample PDF
 

On the basis of drug type, the anti-infective lyophilized injectable drugs market size is anticipated to reach over USD 311 billion by 2032 attributed to the surging incidences of various infectious diseases, such as HIV, herpes simplex virus, influenza, and hepatitis virus. It has been estimated that nearly 1 in 6 people aged between 14 to 50 years are affected by hepatitis virus infection and about 1.2 million people are presently suffering from HIV in the U.S.
 

Lyophilized Injectable Drugs Segmentation by Indication

To get more details on this report: Request Free Sample PDF
 

Based on indication, the lyophilized injectable drugs market share from the oncology segment may surpass USD 290 billion by 2032 due to the increasing cancer treatment awareness worldwide. The surge in technological developments has led to the growing number of R&D activities related to cancer. There has also been a significant rise in the instances of launches of new cancer medications by prominent biopharmaceutical companies. The escalating concerns pertaining to the rising cancer death rates will also play a key role in the segment progression.
 

Lyophilized Injectable Drugs Segmentation by Packaging

With respect to packaging, the lyophilized injectable drugs market share from the cartridges segment is poised to depict 13.7% CAGR by 2032 driven by benefits, such as ease of use and enhanced accessibility. Single chamber and dual-chamber cartridges have grown widely popular as they are suitable for simple drug delivery and pen systems.  The access to low residual moisture and careful calibration with pen systems are other factors driving the demand for cartridge-packaged lyophilized injectable drugs.
 

Lyophilized Injectable Drugs Regional Analysis

North America recorded over 47% share of the lyophilized injectable drugs market in 2022. The rising prevalence of chronic diseases has led to the surging need for well-established healthcare infrastructure in the region. According to the CDC (Centers for Disease Control and Prevention), 6 in 10 adults across the U.S. suffer from a chronic disease. The robust presence of favorable reimbursement scenario will contribute to the regional market expansion.  
 

Lyophilized Injectable Drugs Industry Leaders

Some leading companies in the lyophilized injectable drugs market comprise Gilead Sciences, Inc, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Cipla Limited, Novo Nordisk A/S, SFresenius SE & Co. KGaA (Fresenius Kabi), anofi, Aurobindo Pharmaceuticals, Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Zydus Group, Vetter Pharma, and Johnson & Johnson Services, Inc
 

Lyophilized Injectable Drugs Market News

• Bristol Myers Squibb, in June 2022, acquired Turning Point Therapeutics to gain the portfolio of experimented medicines that target the most common mutations in oncogenesis, including repotrectinib. The acquisition also helped the firm to enhance its operation capabilities and expand its offerings.
   
• In September 2022, Sanofi obtained the U.S. FDA approval for Dupixent (dupilumab) that is used in the treatment of skin diseases with inflammation in children aged below 5 years.
   

The lyophilized injectable drugs market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Drug type

• Anti-infectives
• Anti-neoplastics
• Anticoagulants
• Hormones
• Antiarrhythmics
• Other drug types

By Indication

• Autoimmune diseases
• Respiratory diseases
• Gastrointestinal disorders
• Oncology
• Cardiovascular diseases
• Infectious diseases
• Metabolic disorders
• Other indications

By Type of Delivery

• Prefilled diluent syringes
• Multi-step devices

By Packaging

• Vials
• Cartridges
• Prefilled devices

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Belgium
  • Netherland
  • Norway
  • Switzerland
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • New Zealand
  • Singapore
  • Thailand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Iran
  • Rest of Middle East & Africa